TabletsTablets
Schedule H (Prescription Required)AntimalarialsCode: 305

Chloroquine Phosphate Tablets 250 mg

Generic Formulation:Chloroquine Phosphate Tablets IP 250 mg
Pack Size:10's
Common Commercial Brand Equivalents:Market reference only
Jan Aushadhi MRP
₹5
Brand Estimate*
₹8.52
Estimated Savings:₹3.52 (41% saved)
Find a Kendra Near You
*Statutory price across 21,118 listed Kendras
Clinical InformationReport Error

Clinical Overview

Chloroquine Phosphate is a 4-aminoquinoline antimalarial and antirheumatic agent. It accumulates within the acidic food vacuole of the malaria parasite, inhibiting the biocrystallization of toxic heme into non-toxic hemozoin; uncomplexed heme lyses parasite membranes. Indicated for the treatment and prophylaxis of malaria caused by susceptible Plasmodium vivax, P. malariae, and P. ovale, as well as extraintestinal amoebiasis (amoebic liver abscess).

Active Pharmaceutical Ingredients

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 305.Report inaccuracy

Usage Guidelines

Take orally with meals or milk to avoid nausea and vomiting. Follow exact loading and maintenance dosing prescribed by the doctor. For malaria prophylaxis, take once weekly on the same day each week starting 1-2 weeks before travel.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: Nausea, vomiting, headache, dizziness, visual blurring, pruritus (especially in dark-skinned individuals), mild diarrhea. Rare/Severe: Irreversible retinal toxicity/maculopathy (bull's-eye retinopathy with prolonged high doses), cardiomyopathy, QT prolongation, seizures, and hemolytic anemia in G6PD deficiency.

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

Contraindicated in patients with retinal disease or porphyria. Long-term use requires baseline and periodic ophthalmologic examinations. Caution in patients with G6PD deficiency, epilepsy, or cardiac conduction disorders.

Schedule H (Prescription Required)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.